This new vaccine is 96% effective against coronavirus that causes COVID-19
The Novavax COVID-19 vaccine is 96% effective against the original mutation. But what about the variants?
- The vaccine led to no severe illnesses or deaths from COVID-19.
- The data comes from a late-stage trial in the United Kingdom. The data puts the vaccine closer to emergency approval.
So what about the COVID-19 variants?
- If you combine data from the U.K. variant and the normal variant, the vaccine was about 90% effective.
In South Africa, the Novavax vaccine was 55% effective but prevented severe illness and death, per CNBC.
Why this is good news
- “I did not think it was possible to have a vaccine prevent 96% of any respiratory disease,” he said, per Time magazine. “That’s outstanding, and I’m personally ecstatic. If you had asked me a year ago (to predict) the very best vaccine we could expect, I would have said 80% or 85% efficacy against any respiratory disease would be pretty amazing.”
The data comes from the United Kingdom and South Africa trials. A third trial in the United States is underway right now with 30,000 participants. But it won’t have results for a few more months, according to USA Today.